Valuation: Spero Therapeutics, Inc.

Market Cap 69.88M 61.67M 58.35M 52.92M 99.21M 6.71B 100M 700M 270M 3.42B 262M 257M 11.02B P/E 2026 *
-2.07x
P/E 2027 * -11.4x
Enterprise Value 69.88M 61.67M 58.35M 52.92M 99.21M 6.71B 100M 700M 270M 3.42B 262M 257M 11.02B EV / Sales 2026 *
271x
EV / Sales 2027 * -
Free-Float
77.39%
Yield 2026 *
-
Yield 2027 * -
1 day+2.92%
1 week-1.59%
Current month+1.64%
1 month+1.64%
3 months-43.89%
6 months-44.64%
Current year-46.78%
1 week 1.17
Extreme 1.17
1.29
1 month 1.1
Extreme 1.1
1.44
Current year 1.08
Extreme 1.08
3.08
1 year 1.08
Extreme 1.08
3.08
3 years 0.51
Extreme 0.5052
3.22
5 years 0.51
Extreme 0.5052
18.84
10 years 0.51
Extreme 0.5052
23.64
Manager TitleAgeSince
Chief Executive Officer 47 2025-01-09
Chief Tech/Sci/R&D Officer 69 2026-07-26
Chief Operating Officer 58 2023-01-31
Director TitleAgeSince
Chairman 69 2013-12-31
Director/Board Member 62 2015-08-31
Chairman 56 2025-01-09
Date Insider Type Main position Quantity % Market Cap. Importance
8/3/26 Free

Chief Technology Officer

486,986 0.8411%
5/4/26 Sell

Chief Executive Officer

-25,240 0.0436%
2/6/26 Sell

Chief Executive Officer

87,917 0.1560%
Change 5-day change 1-year change 3-year change Capi.($)
+2.50%-1.59%-34.04%+4.20% 69.88M
+4.16%-0.30%+58.96%+94.17% 71.53B
-0.19%+1.32%+37.20%+81.33% 60.12B
-1.51%+2.39%+9.10%+36.79% 48.85B
+0.84%+1.22%+42.74%+39.84% 44.28B
+1.27%+9.09%+345.55%+695.07% 43.83B
+1.88%+2.36%+9.66%+109.31% 41.53B
-0.67%-0.45%+4.47%+46.37% 30.13B
+4.77%+6.46%+41.54%+22.78% 27.98B
-0.32%-2.30%-19.71%+355.74% 25.25B
Average +1.36%-0.74%+49.55%+148.56% 39.36B
Weighted average by Cap. +1.29%+0.62%+63.86%+155.52%

Financials

2026 *2027 *
Net sales 258K 228K 215K 195K 366K 24.76M 370K 2.58M 996K 12.64M 969K 948K 40.68M -
Net income -33.46M -29.52M -27.93M -25.33M -47.5M -3.21B -47.96M -335M -129M -1.64B -126M -123M -5.28B -51.5M -45.45M -43M -39M -73.11M -4.94B -73.84M -516M -199M -2.52B -193M -189M -8.12B
Net Debt - -
Logo Spero Therapeutics, Inc.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Employees
25
Date Price Change Volume
26-09-30 US$1.230 +2.50% 69,156
26-09-29 US$1.200 +0.84% 334,908
26-09-28 US$1.190 -3.25% 393,255
26-09-25 US$1.230 -1.60% 542,770
26-09-24 US$1.250 -0.79% 476,931
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.200USD
Average target price
5.000USD
Spread / Average Target
+316.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SPRO Stock